Deltec Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Deltec Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,854	Closed	-$828K	–	310
2021 Q1	$828K	Buy	+3,854	New	+$847K	0.12%	135
2015 Q1	–	Sell	-5,750	Closed	-$683K	–	160
2014 Q4	$683K	Buy	+5,750	New	+$648K	0.15%	82

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Deltec Asset Management's VRTX Position: Q2 2021 in Review

Deltec Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 3,854 shares — an estimated $828K sold.

Deltec Asset Management first reported a position in VRTX in Q4 2014 and held it in 2 quarters. The position peaked at $828K in Q1 2021. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Deltec Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Deltec Asset Management sold 3,854 Vertex Pharmaceuticals shares in Q2 2021, an estimated $828K.
Deltec Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2014 and held it in 2 quarters.
Deltec Asset Management's Vertex Pharmaceuticals position peaked at $828K in Q1 2021.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Deltec Asset Management's 13F filing for Q2 2021, filed 15 Jul 2021.